| Document |
Document Title |
|
WO/2022/197993A1 |
Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dy...
|
|
WO/2022/194240A1 |
Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
|
|
WO/2022/196258A1 |
Provided is an onium salt for a resist composition which is highly sensitive to particle rays or electromagnetic waves, and specifically, to electron rays or extreme ultraviolet radiation. The onium salt is represented by a formula sel...
|
|
WO/2022/197658A1 |
Compounds that induce expression of ATP-binding cassette transporter Al (ABCA1 ) without lipogenesis are provided, as are methods of using the same to treat or prevent type 2 diabetes or dementia.
|
|
WO/2022/188514A1 |
The present application relates to the technical field of organic electroluminescence, and relates to an organic compound, an electronic element comprising same, and an electronic device. The organic compound has a structure as shown in ...
|
|
WO/2022/191278A1 |
A compound which is represented by formula (1). (In formula (1), A represents a substituted or unsubstituted aromatic hydrocarbon ring group which has a fused ring composed of 5 or more rings, while containing a nitrogen atom as a part o...
|
|
WO/2022/191570A1 |
The present invention relates to a high-efficiency organic light-emitting device having excellent light-emitting characteristics in light-emitting efficiency, etc. by employing an anthracene derivative compound having a characteristic st...
|
|
WO/2022/192162A1 |
Pharmaceutical compositions of the invention comprise heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.
|
|
WO/2022/191312A1 |
[Abstract] [Problem] To provide a method for producing a dealkoxyphenylation product with high yield from a substrate, e.g., a sugar, which is bonded to an alkoxyphenyl group through an oxygen atom. [Solution] A substrate that is bonded ...
|
|
WO/2022/184111A1 |
The present invention relates to the technical field of compounds. Disclosed are a plurality of small molecule compounds that are specifically bound to a tau protein and an application thereof. The chemical structures of these small mole...
|
|
WO/2022/183798A1 |
The present application relates to an organic compound, and an organic electroluminescent device and an electronic apparatus using same. The structure of the organic compound is as represented in formula (1). When the organic compound of...
|
|
WO/2022/179524A1 |
A tricyclic compound as represented by formula (I), a preparation method therefor, and an application thereof as an HIF2α inhibitor.
|
|
WO/2022/181793A1 |
The present invention provides: a compound that is represented by formula (1) (in the formula, the combination of X and L represents a combination or the like in which X is a nitrogen atom and L is an oxygen atom or NH, n represents 1 or...
|
|
WO/2022/175959A1 |
The present invention is directed to compounds or compositions comprising thereof, and to uses thereof such as for in prevention or treatment of a disease or a disorder associated with an elevated concentration of a branched chain amino ...
|
|
WO/2022/174468A1 |
Disclosed is a method for preparing a 2-iodoheterocyclic aryl ether at room temperature, comprising adding an alkali metal hydride and a phenol to a solvent, then adding a diiodoheterocyclic aromatic hydrocarbon, and performing a reactio...
|
|
WO/2022/174883A1 |
The present invention relates to a compounds of general formula (I) inhibiting both lysophosphatidic acid receptor 1 (LPA1) and receptor 2 (LPA2), particularly the invention relates to compounds that are 5-membered heterocyclyl derivativ...
|
|
WO/2022/170737A1 |
A thienopyrimidine compound (a compound of formula N) and a preparation method therefor. Specifically, the provided preparation method comprises the steps of: (a) in a solvent A, reacting, in the presence of an organic base and acyl chlo...
|
|
WO/2022/173329A1 |
The invention relates to a novel derivative of 2-acetamido-6-hydroxy-benzothiophene of general formula I, or a pharmaceutically acceptable salt thereof, which has antiviral activity and can be used for treating viral diseases caused by r...
|
|
WO/2022/172685A1 |
Provided are a method for forming a resist pattern having excellent performance including sensitivity during a light exposure process, LWR performance and CDU performance even when a next-generation light exposure technology is applied t...
|
|
WO/2022/170519A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2022/167866A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...
|
|
WO/2022/167867A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid o...
|
|
WO/2022/166870A1 |
Disclosed in the present invention is a preparation method for a tetra-substituted allenoic acid compound based on a palladium catalytic system, that is, an optically active allenoic acid compound having axial chirality is directly const...
|
|
WO/2022/161789A1 |
The present invention relates to a new process for the production of specific intermediates, which are preferably used in the production of vitamin A, vitamin A acetate, or β-carotene and derivatives thereof, e.g. canthaxanthin, astaxan...
|
|
WO/2022/163209A1 |
A carbon dioxide absorber which comprises an amine compound (A) having a heterocyclic structure (X) selected from among oxygen-containing heterocyclic structures and sulfur-containing heterocyclic structures and which has a content of th...
|
|
WO/2022/157499A1 |
The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
|
|
WO/2022/156005A1 |
The present invention relates to the field of fine chemical engineering, and in particular, to a method for preparing an α-acyloxy-thioether derivative. The technical key points are as follows: compound A, carboxylic acid B, a sodium sa...
|
|
WO/2022/158758A1 |
Provided is an organic compound which contributes to substantial improvements in the luminous efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention c...
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/148466A1 |
A fused ring compound and an application thereof in an organic electronic device, and in particular, an application in an organic light-emitting diode. Further recited is an organic electronic device containing the fused ring compound, a...
|
|
WO/2022/038365A9 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
|
|
WO/2022/149617A1 |
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...
|
|
WO/2022/144019A1 |
Disclosed are an organic mixture and an application thereof in an organic electronic device, especially in an organic electroluminescent diode. Also disclosed is the organic electronic device comprising the mixture, especially the organi...
|
|
WO/2022/144018A1 |
A mixture and an application thereof in an organic electronic device, especially an application in an organic electroluminescent diode. An organic electronic device comprising the mixture, especially the organic electroluminescent diode,...
|
|
WO/2022/142821A1 |
The present invention relates to the technical field of liquid crystal compounds, and specifically, to a liquid crystal compound, a preparation method therefor, and an application thereof. The liquid crystal compound has the structure sh...
|
|
WO/2022/139179A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/140520A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/140297A1 |
The disclosure relates to novel compounds and methods of use of the compounds to maintain the Gαi2 protein in its inactive GDP -bound state. The disclosure describes the knockdown or inhibition of Gαi2 negatively regulated migration of...
|
|
WO/2022/131697A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electronic element using same; and an electronic device thereof.
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/122975A1 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition c...
|
|
WO/2022/124499A1 |
The present specification pertains to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2022/116826A1 |
The present invention belongs to the technical field of liquid crystal compounds, and specifically relates to a liquid crystal compound and method for preparation thereof and application thereof. The liquid crystal compound has the struc...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/113814A1 |
Provided are: a radiation-sensitive resin composition able to exhibit satisfactory levels of sensitivity, LWR performance and CDU performance; a method for forming a pattern; and an onium salt compound. This radiation-sensitive resin com...
|
|
WO/2022/105986A1 |
The present invention relates to novel physiological cooling agents, cooling agent mixtures containing said novel substances, mixtures of cooling agents with flavours, the use of said cooling agents and objects and final preparations for...
|
|
WO/2022/106452A2 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2022/108259A1 |
The present specification provides a compound of formula 1 and an organic light-emitting device comprising same.
|
